The judges mentioned the statute of limitations had run out on the group’s problem to the unique approval. Nevertheless it mentioned that was not the case for the following actions starting in 2016 that expanded entry to the drug. The courtroom characterised the FDA as willingly ignoring the potential penalties of increasing entry to mifepristone.